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Depletion of ribosomal protein 
S19 causes a reduction of rRNA 
synthesis
Giada Juli1, Angelo Gismondi1, Valentina Monteleone1, Sara Caldarola1, Valentina Iadevaia2,†, 
Anna Aspesi3, Irma Dianzani3, Christopher G. Proud2,‡ & Fabrizio Loreni1
Ribosome biogenesis plays key roles in cell growth by providing increased capacity for protein 
synthesis. It requires coordinated production of ribosomal proteins (RP) and ribosomal RNA (rRNA), 
including the processing of the latter. Here, we show that, the depletion of RPS19 causes a reduction 
of rRNA synthesis in cell lines of both erythroid and non-erythroid origin. A similar effect is observed 
upon depletion of RPS6 or RPL11. The deficiency of RPS19 does not alter the stability of rRNA, but 
instead leads to an inhibition of RNA Polymerase I (Pol I) activity. In fact, results of nuclear run-on assays 
and ChIP experiments show that association of Pol I with the rRNA gene is reduced in RPS19-depleted 
cells. The phosphorylation of three known regulators of Pol I, CDK2, AKT and AMPK, is altered during 
ribosomal stress and could be involved in the observed downregulation. Finally, RNA from patients with 
Diamond Blackfan Anemia (DBA), shows, on average, a lower level of 47S precursor. This indicates that 
inhibition of rRNA synthesis could be one of the molecular alterations at the basis of DBA.
Ribosome biogenesis is an energetically expensive process that occurs in the nucleolus and is tightly regulated 
according to cell growth conditions. It requires the activity of all three nuclear RNA polymerases (Pol), each of 
them dedicated to the transcription of a different ribosomal components1. Specifically, Pol II produces ribosomal 
protein mRNAs that are transported in the cytoplasm and translated into ribosomal proteins (RPs) according to 
cell growth rate2,3. Pol III synthesizes the 5S ribosomal RNA (rRNA), and Pol I is dedicated to the synthesis of 
the other rRNAs. Primary product of Pol I transcription is 47S pre-rRNA (also called 45S), which includes 18S, 
5.8S and 28S rRNAs4. Once transcribed, 47S pre-rRNA is cleaved at specific sites (endo- and exo-nucleolitic 
cleavages) by RNAses to produce a series of characteristic intermediates (45S’, 41S, 32S, 30S, 21S, 12S), and finally, 
the mature rRNA species4–6. Pol I activity accounts for up to 60% of transcription in a eukaryotic cell7. It requires 
a number of accessory factors, which facilitate polymerase recruitment, initiation, promoter escape, elongation 
and termination1.
The transcription of rDNA is dependent on three basal transcription factors: the “selectivity complex” (SL1 
or TIF-IB), the HMG1 box architectural upstream binding factor (UBF) and the Pol I. Both UBF and SL1 make 
direct contacts with two sequence elements known as the upstream control element (UCE) and the core. In 
the case of UBF, it probably binds to these promoter elements as a dimer. UBF is thought to bind the promoter 
first, enabling the subsequent recruitment of SL1 and Pol I. The initiation factor TIF-IA is also part of this com-
plex5,8,9. In addition, many accessory factors are now known to assist at each stage of this transcription cycle, 
some of which allow the integration of transcriptional activity with metabolic demands1. Stringent regulatory 
mechanisms presumably operate to ensure a precise balance between the requirement for, and the availability of, 
rRNA. This is necessary to allow the cells to control their capacity for protein synthesis in response to changing 
metabolic needs, linked, e.g., to cell growth and proliferation. In fact, transcription by Pol I is low when nutrients 
or mitogens are limiting, but is enhanced when the availability of these growth stimuli increases. In addition, Pol 
I transcription is regulated in response to a range of cellular stresses and during many fundamental cellular pro-
cesses, such as cellular differentiation and cell cycle5,10–12. A range of cellular control pathways has been shown to 
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mediate such acute changes in rRNA synthesis. Final effectors of these pathways directly regulate the activity of 
the Pol I transcription machinery, either positively or negatively5,9,12.
Interest in mammalian ribosome biosynthesis has been stimulated by its involvement in the pathogenesis of 
a number of inherited and acquired diseases including cancer13,14. Mutations in genes encoding components of 
the ribosome or proteins involved in ribosome maturation, assembly, or export have been identified as the cause 
of a variety of clinical symptoms13. For instance, Diamond Blackfan Anemia (DBA), characterized by a reduced 
number of erythroid precursors, is caused by mutations in one of several genetic loci which code for RPs of both 
small and large ribosomal subunit13,15,16.
Most RPs interact with rRNA and might function as RNA chaperones, not only during the assembly of the 
ribosome particle, but also in the stabilization of important domains of the rRNA during its maturation4. RP 
depletion, with a few exceptions, leads to the accumulation of specific rRNA precursors, highlighting their indi-
vidual role in specific steps of the rRNA processing17,18. For instance, it has been shown that the depletion of 
RPS19 in human cell lines by siRNA causes decreased ribosome synthesis with accumulation of rRNA 21S17–19.
In this study, we aimed to address the effect of RPS19 deficiency on rRNA synthesis. We found that the deple-
tion of RPS19 causes a reduction of 47S rRNA in a number of cell lines of different origins. The lower level of 
rRNA precursors reflects decreased recruitment of Pol I onto the rDNA promoter. Moreover, the analysis of a 
number of RNA samples from DBA patients shows, on average, a lower level of 47S rRNA with respect to con-
trol samples. This suggests that the molecular alterations that occur in DBA cells include a reduction in rRNA 
synthesis.
Results
Depletion of RPs causes a decrease of the 47S rRNA level. A number of publications have reported 
that interference with RP expression affects rRNA maturation17–20. We observed the same phenomenon in a 
K562 modified cell line (K562C), which is stably transduced with a lentiviral vector inducible for the expression 
of siRNA specific for RPS19 mRNA21. As shown in Fig. 1, doxycycline treatment of K562C induces alteration 
in the processing of pre-rRNA, indicated by accumulation of 21S pre-rRNA on a Northern blot probed with an 
oligonucleotide that anneals to the 5′ end of ITS1. In these experiments we noticed that the level of 47S precur-
sor was also affected and decided to further address rRNA synthesis. To determine if RP depletion causes also a 
decrease of rRNA synthesis, we analyzed the level of the short-lived 47S pre-rRNA in a number of cell lines which 
had been manipulated to inhibit the synthesis of specific RPs: 1) K562C and TF-1C cells (similarly inducible 
for RPS19 depletion) treated with doxycycline (+dox); 2) HEK293 and 22RV1 cells transiently transfected with 
siRNA specific for RPS19; 3) K562 cells transiently transfected with siRNA specific for RPS19, RPS6 and RPL11. 
As a control, we used 1) untreated K562C and TF-1C cells (−dox), 2) K562S cells inducible for the expression of 
a scrambled siRNA treated with doxycycline (+dox); or 3) transient transfection of unrelated siRNA (siCNT). 
RNA levels were analyzed either by northern blot or by quantitative RT-PCR and the results are reported in Fig. 2. 
In all the cell lines, the depletion of RPS19 or the other RPs, verified by RT-qPCR, caused a reduction of 47S 
rRNA precursor to about 40–60% with respect to controls, that include doxycyclin-treated K562 cells (Fig. 2a,b). 
In addition, RPS19 overexpression after its siRNA-mediated depletion in HEK293 cells causes a recovery of 47S 
rRNA level (Fig. 2c), showing the effect is due to altered RPS19 levels.
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Figure 1. rRNA maturation during RPS19 depletion. (a) Total RNA was extracted from K562C cells, 
untreated (−dox) or incubated with doxycycline for 4 days to induce an siRNA against the S19 mRNA (+dox) 
and analyzed by Northern blot with a probe for the ITS1 region. The figure shows a PhosphorImager image with 
major rRNA species indicated by black arrow points. (b) Scheme of rRNA processing pathways in mammals. 
The name of rRNA precursors and major cleavage sites are indicated. The approximate position of the probe is 
shown within the ITS1.
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Figure 2. Analysis of 47S pre-rRNA level. (a) K562C cells were incubated with vehicle (−dox) or with 
doxycycline for 4 days (+dox) whereas K562, 22RV1 and HEK293 cells were transfected with unrelated siRNA 
(siCNT) or siRNA specific for RPS19 (siS19), RPS6 (siS6) or RPL11 (siL11). Total RNA was analyzed by RT-
qPCR with primers specific for 5′ETS region of 47S rRNA and β-actin. The results of triplicate RT-qPCR from 
three independent RNA preparations are reported as a column plot of the mean ± s.e.m. of 47S rRNA/actin 
mRNA (siS19 is from a single triplicate experiment). (b) Total RNA extracted from K562S cells incubated with 
doxycycline for 4 days to induce a scrambled siRNA (+dox), from K562C or from TF-1C cells, untreated (−dox) 
or incubated with doxycycline for 4 days to induce an siRNA against the S19 mRNA (+dox) was analyzed 
by Northern blot with a 5′ETS oligonucleotide probe (indicated in Fig. 1b). An example of Northern blot is 
shown on the left. Uncropped original images are shown in Supplementary information. The results from three 
independent RNA preparations are reported as a column plot of the mean ± s.e.m. of 47S rRNA/actin mRNA. 
(c) HEK293 cells were transfected with control (siCNT) or RPS19 specific siRNA (siS19). Part of siS19 cells were 
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47S rRNA stability and synthesis. To investigate whether the reduction of 47S rRNA was due to an 
increase of rRNA turnover, we treated the cells with a Pol I inhibitor while monitoring the kinetics of rRNA 
degradation both in control and RPS19-depleted cells. K562C cells were treated for different times (0, 10, 30 
and 60 min) with low doses (20 ng/ml) of Actinomycin D (Act D), and the levels of rRNA species were analyzed 
by Northern blot. The results, reported in Fig. 3a, indicate that the rate of rRNA degradation did not increase in 
RPS19-deficient cells. This suggests that 47S decrease induced by RPS19 deficiency is not due to faster decay but 
likely reflects inhibition of transcription.
To address the hypothesis that RPS19 depletion inhibits the transcriptional activity of Pol I, we performed a 
nuclear run-on assay which, by measuring the amount of chromatin-bound (active) polymerase, allows one to 
evaluate the transcription initiation rate. The results show that Pol I activity in several different regions of rRNA 
genes is reduced after RPS19 depletion. No effect was observed for Pol III-dependent transcription of 5S rRNA 
genes, or for the Pol II-dependent transcription of the actin gene which serve as controls (Fig. 3b). Therefore, our 
results indicate that RPS19 depletion inhibits specifically the activity of Pol I.
To further study Pol I activity during ribosomal stress, we performed a chromatin immunoprecipitation assay 
(ChIP) in HEK293 cells after the depletion of RPS19 to analyze the binding of Pol I around the promoter (H1) and 
within the coding region (H4) of the major rRNA genes. In addition, we analyzed the binding of UBF within the 
H4 region in control and RPS19-depleted K562C cells. As shown in Fig. 3c, RPS19 deficiency causes a decrease 
in the binding of Pol I to both portions of rDNA and of UBF to H4. In fact, the presence of both H1 and/or H4 
DNA segments in Pol I or UBF immunoprecipitate is reduced in RPS19-depleted cells (Fig. 3c). As an additional 
control we measured the level of Pol I by Western blot with specific antibodies of control and RPS19-depleted 
K562C cells. As shown in Fig. 3d, Pol I level is not affected by RPS19 depletion
Pol I regulators affected by ribosomal stress. To address the mechanism underlying the inhibition 
of rRNA synthesis, we measured the level and the phosphorylation status of known regulators of Pol I activity. 
On the basis of preliminary analysis and published reports22–24, we considered the following proteins: 1) 
cyclin-dependent kinase 2 (CDK2), 2) AKT (protein kinase B), and 3) the AMP-activated protein kinase (AMPK).
CDK2 is an important component of the cell cycle machinery. We have previously reported that RPS19 deple-
tion causes inhibition of cell cycle progression, a proliferation decline and an increase in the CDK inhibitor 
p27kip1 25. Pol I transcription is enhanced via phosphorylation of the basal transcription factor UBF by CDK2/
cyclin complexes24. Thus, it can be hypothesized that in our experimental models after ribosomal stress, p27kip1 
binds to and inhibits CDK2 activity leading to downregulation of rRNA synthesis.
The second regulatory protein analyzed is AKT, which is involved in signaling via both mammalian target of 
rapamycin complexes, mTORC1 and mTORC2. mTORC1 drives ribosome biogenesis26, by promoting activation 
of Pol I and Pol III and the synthesis of RPs. mTORC2 has been shown to interact with ribosomes, and knock-
down of ribosomal proteins causes a decrease in mTORC2 signaling27. In addition, AKT has been reported to be 
necessary for Pol I–driven rDNA transcription22 and we have recently shown that it is involved in the response 
to ribosomal stress28.
Finally, a number of observations in our experimental models as well as published studies, are consistent with 
the activation of AMPK in response to ribosomal stress23,29. AMPK is activated under many cellular stress con-
ditions such as hypoxia, nutrient deprivation or oxidative stress30. It has been shown that AMPK down-regulates 
rRNA synthesis under glucose restriction by phosphorylating the Pol I-associated transcription factor TIF-IA31. 
Therefore, this kinase was also a good candidate to be a component of the signaling activated by ribosomal stress.
To analyze the activity of Pol I regulators, K562C cells (only for CDK2) or 22Rv1 cells (for all three) were 
treated to induce RPS19 deficiency. Cell extracts were analyzed by western blot with antibodies specific for CDK2 
total or phosphorylated on Thr160, AKT total or phosphorylated on Ser473, AMPK total or phosphorylated on 
Thr172 plus ‘loading’ controls (RPS19 and GAPDH). The results, reported in Fig. 4, show that RPS19 depletion 
causes a reduction of the active forms of CDK2 and AKT (both positive regulators of Pol I) and an increase in 
the phosphorylation of Thr172, a key activating site in AMPK (an inhibitor of Pol I). Thus, all three kinases could 
potentially mediate the downregulation of Pol I activity caused by ribosomal stress.
47S rRNA levels in DBA patients. Alteration of rRNA processing has been observed in cultured cells 
after depletion of RPs and confirmed to occur in cells from DBA patients18,19,32. It has been proposed that this 
finding could even be exploited as a diagnostic tool33. For this reason, we decided to investigate if the decrease 
in rRNA synthesis caused by RP depletion could be detected in samples from DBA patients. To this end, RNA 
was purified from blood samples of 9 control donors (4 males, 5 females; age from 9 to 55) and 10 DBA patients 
(6 males, 4 females; age from 5 to 40). Ribosomal RNA level was analyzed by quantitative RT-PCR with primer 
specific for the first part of the ETS region in the 47S rRNA precursor and for β-actin mRNA as a control. The 
results, reported in Fig. 5 and Table 1, indicate that, on average, the level of the 47S pre-rRNA species is lower in 
DBA patients compared to controls. However the large variability in 47S levels, both in the patients and in the 
controls does not allow this analysis to be statistically significant and to be used as diagnostic tool. It could be that 
then transfected with an RPS19 overexpressing plasmid (siS19 + S19). RNA was analyzed by RT-qPCR with 
primers specific for 5′ETS region of 47S rRNA and β-actin. The results of triplicate qPCR from three Reverse 
Transcription reactions are reported as a column plot of the mean ± s.e.m. of 47S rRNA/actin mRNA. (d) RNA 
isolated from cells treated as described in panel a, was analyzed by RT-qPCR with primers specific for RPS19, 
RPS6, RPL11 and β-actin. The results of triplicate RT-qPCR from three independent RNA preparations are 
reported as a column plot of the mean ± s.e.m. of RP mRNA/actin mRNA.
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Figure 3. Analysis of rRNA stability and synthesis. (a) Control (−dox) or RPS19-depleted (+dox) K562C 
cells were treated with actinomycin D (20 ng/ml) for different times (0, 10′, 30′ and 60′) and total RNA was 
analyzed by Northern blot with probes specific for 5′ETS region of 47S rRNA and β-actin mRNA. Uncropped 
original images are shown in Supplementary information. Quantification of the signals is reported in the graph. 
(b) Nuclear run-on assay. Different amount of plasmid DNA (10 or 20 μg) including sequences of 5′ETS, 18S, 
two regions of 28S, β-actin mRNA, pCDNA3 and rRNA 5S were spotted on membrane and incubated with 
32P-labeled RNA from untreated (−dox) or RPS19-depleted (+dox) K562C cells (left panel). The average 
of the two signals (10 and 20 μg) normalized for β-actin, is reported in the bar graph in the right panel. A 
schematic diagram of 47S pre-rRNA indicating the regions used in nuclear run-on assay is shown in the lower 
panel. (c) Chromatin cross-linking and immunoprecipitation assay (ChIP) was performed with Pol I-specific 
antibodies in HEK293 cells transfected for 72 h with control (CNT) or RPS19-specific siRNA (siS19), and with 
UBF-specific antibodies in K562C cells untreated (−dox) or incubated with doxycycline for 4 days (+dox). 
Associated DNA was analyzed by qPCR using primers specific for a sequence around the promoter (H1) or 
within the coding region (H4) of human rDNA. Right panel shows an ethidium bromide-stained agarose gel of 
input and Pol I-associated DNA (H4 region) amplified by PCR. The positions of H1 and H4 regions are shown 
in the lower panel. Uncropped original images are shown in Supplementary information. (d) Total extracts from 
K562C cells untreated (−dox) or incubated with doxycycline for 4 days (+dox) were analyzed by Western blot 
with the indicated antibodies. Uncropped original images are shown in Supplementary information.
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increasing the number of samples and/or the stratification of the patients into different subsets will render the 
analysis more meaningful.
Figure 4. Protein analysis. Total extracts from K562C cells untreated (−dox) or treated with doxycycline for 4 
days to induce RPS19 depletion (+dox) or from 22Rv1 cells transfected with control (siCNT) or RPS19-specific 
siRNA (siS19) were analyzed by Western blot with the indicated antibodies. Examples of Western from a single 
experiment are shown in the upper panels. Quantification of signals from three independent experiments 
is reported in lower panels as a column plot of the mean ± s.e.m. of the densitometry values normalized by 
GAPDH. The image of total CDK2 in 22Rv1 cells was obtained by cropping two lanes from a single blot. 
Uncropped original images are shown in Supplementary information.
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Figure 5. 47S rRNA level in cells from DBA patients. Total RNA from mononuclear cells of 9 controls or 10 
DBA patients harboring different mutations (indicated in Table 1) were analyzed by RT-qPCR with primers 
specific for 47S and β-actin. The results of triplicate RT-qPCR analyses from each sample are reported as a 
dot plot of 47S rRNA level calculated with the 2−ΔCt method. The orizontal bars indicate the means of the two 
groups of values.
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Discussion
Considering the complexity and importance of ribosome biogenesis, it seems probable that a number of mech-
anisms actively coordinate the production of the different components required to make functional ribosomes. 
Identification of such regulatory circuits may reveal important details of the pathological mechanisms of ribo-
somopathies. One of these controls has been shown to operate at the level of rRNA processing. In fact, the defi-
ciency in any RP causes a block in rRNA maturation with the accumulation of processing intermediates17,34. Here 
we report an additional mechanism that works at the level of rRNA synthesis by inhibiting the activity of Pol I in 
response to RP deficiency, i.e., at a very early stage in ribosome production.
The effects of RPS19 deficiency were analyzed in human cultured cells manipulated to express specific siRNAs. 
These included: the erythroleukemia cell lines K562C and TF-1C inducible for the expression of siRNA against 
RPS19 mRNA; the prostate cancer cell line 22Rv1 and the embryonic kidney cell line HEK293 both transiently 
transfected with siRNA for RPS19. In addition, K562 cells were transiently transfected with siRNA specific for 
RPS19, RPS6 or RPL11. In all cases, we observed that depletion of RPs caused a decrease in the level of 47S rRNA, 
analyzed by Northern blot and/or RT-qPCR. Further analysis indicated that the lower level of 47S rRNA was due 
to a reduction in the activity of Pol I. In fact, treatment of K562C cells with the transcription inhibitor actinomy-
cin D showed that the stability of 47S pre-rRNA was not affected by RP depletion. Moreover, run-on assays and 
ChIP experiments showed that RPS19 deficiency caused a reduction of Pol I activity on rDNA and a reduction of 
the binding of UBF, which is a regulator of Pol I activity, on rRNA5. We conclude that we have identified a novel 
regulatory circuit which coordinates the synthesis of rRNA with the availability of RPs.
It has been shown that most of RPs of the small subunit associate with pre-rRNA and at least some of them are 
required for processing18,20,35. We think that it is unlikely that RP interaction with rRNA could directly affect Pol I 
activity. In addition, proteomic studies indicated an interaction between RPS19 and UBF36 that could play a reg-
ulatory role. However, depletion of RPS6 or RPL11 show an inhibitory effect on rRNA synthesis similar to RPS19 
and it is improbable that multiple RPs regulate Pol I activity by direct interaction. As an alternative, we hypothe-
size that a signaling pathway, activated by defective RP synthesis, targets the transcriptional apparatus for rDNA 
genes. Through immunoblot analysis, we identified several known regulators of Pol I that are affected by riboso-
mal stress. Firstly, in RPS19-deficient cells CDK2 is hypophosphorylated on the activatory site Thr160. It has been 
demonstrated that different Pol I-associated transcription factors are positively regulated by this kinase such as 
TIF-IA and UBF5,37. In particular, it is known that after G1 progression, phosphorylation by CDK2 is required for 
UBF activity and represents a powerful means for modulating the assembly of the transcription initiation com-
plex24. The reduction of CDK2 activity caused by RPS19 depletion may therefore inhibit the recruitment of UBF.
A second molecule which may be involved is AKT. We found that RPS19 depletion caused a decrease in AKT 
phosphorylation on Ser473. AKT signaling activates mTORC1, which drives multiple steps in ribosome biogen-
esis including rRNA synthesis26. AKT is required for Pol I driven rRNA transcription at multiple levels, including 
loading of Pol I onto the rDNA (transcription initiation and promoter escape), and subsequent steps, such as 
transcription elongation and rRNA processing22. Since in our experimental setup ribosomal stress induced a 
decrease of AKT phosphorylation, the deficiency of AKT activity may contribute to the suppression of Pol I 
activity. Ser473 is phosphorylated by mTORC2, which is maintained in an active state through its interaction 
with ribosomes27; thus, depletion of an RP may compromise the activation state of mTORC2 leading to reduced 
phosphorylation of AKT at Ser473, which is involved in its activation.
A third established regulator of Pol I is AMPK which is also activated by ribosomal stress. It has been proposed 
that RP depletion could activate AMPK through the alteration of nucleotide metabolism caused by the degrada-
tion of excess rRNA23. It is known that, when activated, AMPK down-regulates rRNA synthesis by phosphorylat-
ing the RNA polymerase I (Pol I)-associated transcription factor TIF-IA. Phosphorylation by AMPK impairs the 
interaction of TIF-IA with the TBP-containing promoter selectivity factor SL1, thereby precluding the assembly of 
functional transcription initiation complex31. Therefore this kinase could also contribute to the reduction of Pol I 
activity during ribosomal stress. At this stage, we do not know whether one or more of these factors is responsible 
of the downregulation of Pol I activity during ribosomal stress. It is also unclear if the observed Pol I inhibition is 
a consequence or one of causes of nucleolar alteration induced by RP depletion38,39. Although RP depletion is not 
always associated to nucleolar disruption40. Further studies are needed to address this issues.
RNA sample Mutation 47S/ACTIN
1 RPL11 2.5
2 unknown 1.1
3 RPS19 1.6
4 RPS19 1
5 unknown 2.1
6 unknown 0.6
7 unknown 0.2
8 RPL11 2.1
9 RPL5 0.6
10 RPL5 2.6
Table 1.  47S rRNA level in RNA samples from DBA patients. RNA was analyzed by RT-qPCR with primers 
specific for 47S and β-actin in triplicate. The values were calculated with the 2−ΔCt method.
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Finally, we tested if the inhibition of Pol I activity in response to ribosomal stress could be observed in the 
physiological context of blood cells from DBA patients. For this analysis, blood samples were collected from 9 
control donors and 10 DBA patients and RNA was analyzed by RT-qPCR. We found that, on average, the 47S 
rRNA level was lower in RNA samples from DBA patients compared to controls. However, the variability of val-
ues does not allow an unambigous classification of the samples. Additional analysis may lead to the identification 
of a subgroup of patients with more homogeneous values.
Methods
Cell culture and transient transfection. K562C and TF-1C (human erythroleukemia) cells were main-
tained in RPMI 1640 medium. HEK293 (human embryonic kidney) and 22RV1 (human prostate carcinoma 
epithelial) cells were maintained in Dulbecco’s modified Eagle Medium (DMEM) supplemented with 10% fetal 
bovine serum, and antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin) and were incubated at 37 °C 
in a humidified atmosphere with 5% CO2. TF-1C medium was also supplemented with 5 ng/ml Granulocyte- 
Macrophage Colony-Stimulating Factor. TF-1C and K562C cells, expressing inducible siRNA targeting RPS19 
mRNA, were prepared in Karlsson’s laboratory21. K562, HEK293 and 22RV1 (3 × 106) were transiently trans-
fected with 100 nM siRNA and 15 μl of Interferin transfection reagent (Polyplus transfection) according to the 
manufacturer’s protocol. After 48 hours they were re-transfected and 48 hours later were harvested and analyzed 
by RT-qPCR. The RNAi target sequences were: sense, 5′-GAGAUCUGGACAGAAUCGC-3′ for RPS19 and sense 
5′-GACACGCGACUUGUACCAC-3′ for control siRNA (siSCR). In the case of RPS19 overexpression, HEK293 
cells, after double siRNA treatment, were transfected with a RPS19-expressing plasmid (6 μg) 24 hours before 
harvest. Actinomycin treatment of cells was performed using 20 ng/ml for the indicated times.
RNA preparation and northern blot analysis. Total RNA was extracted from cell lines by the protein-
ase K method41. For Northern analysis, RNA was fractionated on formaldehyde-agarose gels and transferred 
to GeneScreen Plus membrane (PerkinElmer Life Sciences), as previously described42. Probe for β-actin was 
prepared by the random primer technique using DNA fragments isolated from plasmids containing PCR ampli-
fied cDNA sequences. Primers for amplification were designed according to sequences present in the NCBI 
Data Bank. For rRNA probes, an oligonucleotide (GTGAGCACGACGTCACCACATCGATCGAAGATC) 
complementary to human rRNA sequence (NR_046235) from position 431 (5′ETS) and an oligonucleotide 
(CCTCGCCCTCCGGGCTCCGTTAATTGATC) complementary to human rRNA sequence (NR_046235) from 
position 5520 (ITS1), were radiolabeled with [γ−32P]-ATP41. Quantitation of Northern blot filters was performed 
with a PhosphorImager (GE Healthcare).
For RNA analysis of DBA patients and controls, a written informed consent was signed by patients and con-
trols or their parents or tutors. Blood was collected into PAXgene Blood RNA Tubes (PreAnalytiX) and RNA was 
purified using the PAXgene Blood RNA kit (PreAnalytiX) following manufacturer’s instructions.
Western blot analysis. Cells were lysed in lysis buffer containing 350 mM NaCl, 1 mM MgCl2, 50 mM 
Tris–HCl (pH 7.5), 0.5 mM EDTA, 0.1 mM EGTA, 1% NP-40, aprotinin 1 mg/ml, phenylmethylsulfonyl fluo-
ride 100 mg/ml and 1% [vol/vol] phosphatase inhibitor cocktail II and III from sigma). Protein concentration 
was measured by Bio-Rad Bradford reagent. Protein sample were prepared by addition of Laemli Sample buffer 
and resolved on 8–10% SDS-PAGE (Sodium dodecyl sulfate–polyacrylamide gel), transferred onto nitrocellu-
lose Protran membrane (Schleicher and Schuell, Italy), and incubated with the following primary antibodies 
and antisera: mouse monoclonal antibody specific for RPS1936, mouse monoclonal anti-GAPDH (Millipore), 
mouse monoclonal anti-Pol I (Santa Cruz Biotechnology, USA), mouse monoclonal anti-total CDK2 (Santa 
Cruz Biotechnology, USA), rabbit polyclonal anti-phospho CDK2 Thr160 (Cell Signaling), rabbit polyclonal 
anti-phospho AKT Ser473 (Cell Signaling Technologies, USA), rabbit polyclonal anti-total AKT (Cell Signaling 
Technologies, USA), rabbit monoclonal anti-phospho AMPK Thr172 (Cell Signaling Technologies, USA), mouse 
monoclonal anti-total AMPK (Santa Cruz Biotechnology, USA). Primary antibodies were revealed using horse-
radish peroxidase-conjugated anti-rabbit or anti-mouse Ab (Jackson Immunoresearch) and the ECL Clarity 
Western substrate detection (BIO-RAD). Quantification analyses were performed by LAS3000 Image System 
(Fuji) and ImageQuant software (GE Healthcare).
Chromatin cross-linking and immunoprecipitation (ChIP). HEK293 cells were treated for 72 h with 
RPS19-specific siRNA and K562C were treated for 4 days with doxycycline. Cross-linking was performed by 
incubating cells with 1% formaldehyde for 10 min at 37 °C. The cells were lysed in 350 μl of lysis buffer (1% SDS, 
10 mM EDTA, 50 mM Tris-HCl, pH 8.1) and sonicated seven times for 20 s. Extracts were immunoprecipitated 
with antibodies specific for Pol I (Santa Cruz) and UBF (Santa Cruz) and DNA isolated from precipitates was 
used for qPCR analysis with primers specific for rDNA region H1 (5′-GGCGGTTTGAGTGAGACGAGA-3′; 
5′-ACGTGCGCTCACCGAGAGCAG-3′) and H4 (5′-CGACGACCCATTCGAACGTCT-3′; 5′-CTCTCCGG 
AATCGAACCCTGA-3′). Input DNA was used for normalization. The samples were analysed with SYBR Green 
dye (Primer Design mix) on an ABI StepOnePlus quantitative PCR instrument (Applied Biosystems).
RT-qPCR analysis. Total RNA (2 μg) was reverse transcribed to cDNA using MMLV enzyme (Promega) 
with random primers following the manufacturer’s protocol. Quantitative PCR on cDNA from cell lines was per-
formed using specific primers for human 47S (5′-GCTGACACGCTGTCCTCTG-3′; 5′-ACGCGCGAGAGAAC 
AGCAG-3′) and β-actin (5′-ACCACCATGTACCCTGGCATT-3′; 5′-CCACACGGAGTACTTGCGCTCA-3′). 
The samples were analysed in triplicate with KAPA SYBR FAST (KAPABIOSYSTEMS) on an Roche Applied 
Science (LC480) quantitative PCR instrument. The comparative Ct method (2−ΔCt) was used to measure amplifi-
cation of rRNA 47S versus β-actin.
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Quantitative PCR on cDNA from DBA patients was carried out using a StepOne real-Time PCR detection system 
(Applied Biosystems). Taqman 2X Universal Master Mix II, no UNG (Applied Biosystems) was used accord-
ing to the manufacturer’s instructions. To detect 47S rRNA precursor, the following oligos were used: forward, 
+132/+149 CCTGCTGTCTCTCGCGC; reverse+198/+181, GGTCAGAGACCCGGACCC; Taqman,+155/174 
AGCGTCCCGACTCCCGGTGC. The Applied Biosystems Human β-actin Endogenus Control (FAMTM/MGB 
Probe, Non-Primer Limited) was used as an endogenous control.
Nuclear run-on. Approximately 108 K562C cells were lysed in hypotonic buffer (10 mM Tris pH 7.9, 10 mM 
NaCl, 5 mM MgCl2) containing 0.1% NP40 and nuclei were purified through a 0.6 M sucrose cushion. Nuclei 
were resuspended in 50 mM Tris pH 8.5, 10 mM NaCl, 5 mM MgCl2, 40% glycerol, 1 mM DTT and then frozen. 
About 2 × 107 nuclei were incubated for 5 min at 25 °C in a buffer containing 150 mM KCl, 1 mM NTP, 0.05 mCi 
α-32P GTP. Labeled RNA was extracted using proteinase K method and resuspended in hybridization buffer 
(GeneScreen Plus). Plasmids containing different regions of rDNA were prepared by inserting PCR products into 
pGemTEasy vector. Cloned sequences, reported by name, start and stop nucleotide position detectable on human 
ribosomal DNA complete repeating unit (GI: 555853) and length in base pairs, are the following: 5′-ETS (from 
1286 to 1920, 635 bp); 18S (from 4101 to 4721, 621 bp); 28S1 (from 9561 to 10320; 760 bp); 28S2 (from 12207 to 
12930; 724 bp). Plasmid DNAs were immobilized on a GeneScreen Plus membrane using a dot-blot apparatus. 
Hybridization was carried out as indicated in GeneScreen Plus manual.
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